All In Biotech

Drug Trial Radar · NCT05176951

A Study to Evaluate the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease

A Phase 2, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease

Last checked: Nov 19, 2026Latest source record: Mar 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

39

Actual

Start

Dec 22, 2022

Primary completion

Mar 14, 2024

Study completion Mar 14, 2024

Sponsor

Lead sponsor
Insmed IncorporatedIndustry
Sponsor type
Industry
First posted
Jan 4, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the safety and tolerability of treprostinil palmitil inhalation powder (TPIP) compared with placebo

Conditions

  • Pulmonary Hypertension

Interventions

  • Treprostinil PalmitilDrug

    Oral inhalation using a capsule-based dry powder inhaler device.

  • PlaceboDrug

    Oral inhalation using a capsule-based dry powder inhaler device.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Experience Any Number of Treatment Emergent Adverse Events (TEAEs)Time frame: Up to Day 140
  2. Number of Participants Who Experience Any Number of Serious Adverse Events (SAEs)Time frame: Up to Day 140
  3. Change from Baseline in Saturation of Peripheral Capillary Oxygenation (SpO2) LevelsTime frame: Pre-, during, and post- 6-minute walk test (6MWT) at Baseline, Week 5, Week 10, and Week 16

Locations

25 sites in 7 countries. Site status is shown where the registry gives one.

  • ARG008

    Buenos Aires, Argentina

  • ARG003

    Barracas, Ciudad Autónoma de BuenosAires, Argentina

  • ARG001

    Rosario, Santa Fe Province, Argentina

  • AUS003

    Camperdown, New South Wales, Australia

  • AUS005

    Macquarie Park, New South Wales, Australia

  • BEL002

    Liège, Belgium

  • GER002

    Berlin, Germany

  • GER012

    Berlin, Germany

  • GER004

    Munich, Germany

  • GER006

    Heidelberg, Baden-Wurttemberg, Germany

  • GER010

    Giessen, Hesse, Germany

  • GER003

    Essen, North Rhine-Westphalia, Germany

  • GER001

    Dresden, Saxony, Germany

  • ITA003

    Naples, Campania, Italy

  • ITA004

    Milan, Lombardy, Italy

  • ITA002

    Monza, Lombardy, Italy

  • ITA001

    Palermo, Sicily, Italy

  • ESP010

    Barcelona, Spain

  • ESP005

    Barcelona, Spain

  • ESP006

    Las Palmas de Gran Canaria, Spain

  • ESP009

    Santiago de Compostela, Spain

  • ESP003

    Palma de Mallorca, Balearic Islands, Spain

  • ESP007

    Oviedo, Principality of Asturias, Spain

  • GBR003

    Glasgow, Lanarkshire, United Kingdom

  • GBR001

    Sheffield, Yorkshire, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.